Literature DB >> 3257705

Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.

D C Blakey1, D N Skilleter, R J Price, P E Thorpe.   

Abstract

The therapeutic activity of ricin A-chain immunotoxins is undermined by their rapid clearance from the bloodstream of animals by the liver. This uptake has generally been attributed to recognition of the mannose-terminating oligosaccharides present on ricin A-chain by receptors present on the non-parenchymal (Kupffer and sinusoidal) cells of the liver. However, we demonstrate here that, in the mouse, the liver uptake of a ricin A-chain immunotoxin occurs in both parenchymal and non-parenchymal cells in equal amounts. This is in contrast to the situation in the rat, where uptake of the immunotoxin is predominantly by the non-parenchymal cells. Recognition of sugar residues on the A-chain portion of the immunotoxin plays an important role in the liver uptake by both cell types in both species. However it is not the only mechanism since, firstly, an immunotoxin containing ricin A-chain which had been effectively deglycosylated with metaperiodate and cyanoborohydride was still trapped to a significant extent by hepatic non-parenchymal cells after it was injected into mice. Secondly, deglycosylation, while eliminating uptake of the free A-chain by parenchymal and non-parenchymal cells in vitro, only reduced the uptake of an immunotoxin by either cell type by about half. Thirdly, the addition of excess D-mannose or L-fucose inhibited the uptake of free A-chain by mouse liver cell cultures by more than 80% but only inhibited the uptake of the native A-chain immunotoxin by about half and had little effect on the uptake of the deglycosylated ricin A-chain immunotoxin. Recognition of the antibody portion of the immunotoxin by liver cells seems improbable, since antibody alone or an antibody-bovine serum albumin conjugate were not taken up in appreciable amounts by the cultures. Possibly attachment of the A-chain to the antibody exposes sites on the A-chain that are recognised by liver cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257705     DOI: 10.1016/0167-4889(88)90005-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

2.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

3.  Endocytosis of ricin by rat liver cells in vivo and in vitro is mainly mediated by mannose receptors on sinusoidal endothelial cells.

Authors:  S Magnússon; T Berg
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

4.  Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.

Authors:  M M Uttenreuther-Fischer; C S Huang; A L Yu
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

Review 5.  Bacterial Toxins for Cancer Therapy.

Authors:  Nour-Imene Zahaf; Gudula Schmidt
Journal:  Toxins (Basel)       Date:  2017-07-28       Impact factor: 4.546

Review 6.  Clinical targeting recombinant immunotoxins for cancer therapy.

Authors:  Meng Li; Zeng-Shan Liu; Xi-Lin Liu; Qi Hui; Shi-Ying Lu; Lin-Lin Qu; Yan-Song Li; Yu Zhou; Hong-Lin Ren; Pan Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.